Lidocaine/tetracaine topical patch - Crescita Therapeutics

Drug Profile

Lidocaine/tetracaine topical patch - Crescita Therapeutics

Alternative Names: Enhanced Formulation - Crescita Therapeutics; HLT Patch; Ralydan; Rapydan; S-Caine™ Patch; Synera; Tetracaine/lidocaine topical patch

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator ZARS
  • Developer Nuvo Research
  • Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Procedural pain
  • Phase II Musculoskeletal pain

Most Recent Events

  • 25 Apr 2017 Lidocaine/tetracaine topical patch licensed to Taro Pharmaceuticals Inc in USA
  • 25 Apr 2017 Crescita Therapeutics has patents pending for lidocaine/tetracaine topical patch (Enhanced Formulation) in USA
  • 01 Apr 2015 The product is still in phase-II development for Musculoskeletal pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top